Cancer immunotherapy: Moving beyond current vaccines

Steven A. Rosenberg, James C. Yang, Nicholas P. Restifo

Research output: Contribution to journalReview articlepeer-review

Abstract

Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.

Original languageEnglish (US)
Pages (from-to)909-915
Number of pages7
JournalNature medicine
Volume10
Issue number9
DOIs
StatePublished - Sep 1 2004

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Cancer immunotherapy: Moving beyond current vaccines'. Together they form a unique fingerprint.

Cite this